GENE
Closed
Genetic Technologies Ltd
0.765
0.000 (0.00%)
Last Update: 28 Jan 2025 17:30:00
Yesterday: 0.765
Day's Range: 0.765 - 0.765
Send
sign up or login to leave a comment!
When Written:
1.14
Genetic Technologies Ltd is a biotechnology company that focuses on developing and commercializing genetic testing services and products. The company is based in Melbourne, Australia, and was founded in 1989.
Genetic Technologies Ltd offers a range of genetic testing services and products, including:
1. BREVAGenplus: a non-invasive genetic test that assesses a woman's risk of developing breast cancer.
2. GeneType for Colorectal Cancer: a genetic test that assesses a patient's risk of developing colorectal cancer.
3. GeneType for Breast Cancer: a genetic test that assesses a patient's risk of developing breast cancer.
4. GeneType for Prostate Cancer: a genetic test that assesses a patient's risk of developing prostate cancer.
In addition to its genetic testing services and products, Genetic Technologies Ltd also offers a range of genetic research and development services, including:
1. Genetic analysis and interpretation.
2. DNA sequencing.
3. Customized genetic testing services.
4. Bioinformatics and data analysis.
Genetic Technologies Ltd has collaborations with several academic institutions and research organizations, including the University of Melbourne, the University of California, and the National Cancer Institute.
The company is publicly traded on the Australian Securities Exchange (ASX: GTG) and the NASDAQ (NASDAQ: GENE).
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Genetic Technologies Ltd offers a range of genetic testing services and products, including:
1. BREVAGenplus: a non-invasive genetic test that assesses a woman's risk of developing breast cancer.
2. GeneType for Colorectal Cancer: a genetic test that assesses a patient's risk of developing colorectal cancer.
3. GeneType for Breast Cancer: a genetic test that assesses a patient's risk of developing breast cancer.
4. GeneType for Prostate Cancer: a genetic test that assesses a patient's risk of developing prostate cancer.
In addition to its genetic testing services and products, Genetic Technologies Ltd also offers a range of genetic research and development services, including:
1. Genetic analysis and interpretation.
2. DNA sequencing.
3. Customized genetic testing services.
4. Bioinformatics and data analysis.
Genetic Technologies Ltd has collaborations with several academic institutions and research organizations, including the University of Melbourne, the University of California, and the National Cancer Institute.
The company is publicly traded on the Australian Securities Exchange (ASX: GTG) and the NASDAQ (NASDAQ: GENE).
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








